image missing
Date: 2024-10-11 Page is: DBtxt003.php txt00004672

Malaria
World Malaria Day 2013

The Financial Times published a Special Report on Combating Malaria for World Malaria Dat 2013 ... in which the US position on the role of the private sector and the Affordable Medicines Facility for malaria (AMFm) is criticized.

Burgess COMMENTARY
I was active with a group called Integrated Malaria Management Consortium for a period of time, and in the process learned a lot about the history of malaria control and the activities of the various organizations engaged in malaria control in the recent few years. My interest in malaria control continues, but now more simply around the issue of metrics that make it possible to say with some certainty, this is what something costs and this is the value of the associated outcomes.

The article in the Financial Times (FT) referred to in the exchange reported below show how difficult it is to make the case that what is being done is the best way to do it ... or not. So much of the measurement is done in a way that, in the end, there are arguments more about opinion and ideology than on the easily understood facts about something.

In the course of the last two weeks I have been modestly engaged with the events surrounding World Malaria Day 2013, including attending a UN event in New York organized by the WHO's Roll Back Malaria campaign. At this luncheon, I raised the question about the value of the outcomes from an expenditure of some $10 billion over the past few years. The various speakers responded to this in a very positive way, because the value is certainly big enough to justify the expenditure.

I did not raise the question of whether or not the same outcome could have been achieved with an expenditure considerably less ... though many in the room knew that this would have been my follow up question in an more analytical setting.

Nor did I raise the question of whether or not the approach being used has any sort of sustainability in a world where public and philanthropic funding is unlikely to be flowing as easily in the future as it has in the past.

In my own view, the state of society is improved when there are substantial malaria control interventions. The progress will be better when the performance of malaria control interventions are the most effective and most efficient.
Peter Burgess

See the FT special report as a pdf

Peter Burgess
Financial Times Special Report on Combating Malaria
Thomas, Chris(GH/HIDN)
Fri, Apr 26, 2013 at 1:11 PM
To: 'Thomas, Chris(GH/HIDN)' Cc: 'smitallm@who.int' , 'MAWG1@listserv.who.int' , 'PMI Core Mail List (USAID)'

Michel: I welcomed the Financial Times Special Report on Combating Malaria. However, I became physically ill after reading Private Sector Role Remains Elusive. We were not contacted by the Financial Times for the story. The article is inaccurate, lacks objectivity, and abuses FT's obligation to be a guardian of the public trust.

I want to set the record straight on the U.S. role “in part of an escalating campaign to undermine programs supporting private sector involvement in the distribution of malaria treatments.” The U.S. Government called for an evidence base for the Affordable Medicines Facility – malaria (AMFm) prior to using U.S. taxpayer funds for its scale up. And we were up front and clear about concerns with an untargeted factory gate subsidy model for reducing prices of Artemisinin based Combination Therapies (ACTs) primarily through the private sector USAID and PMI’s Commitment to Global Efforts to Ensure Prompt Malaria Diagnosis and Treatment.

Mr. Jack mischaracterizes the USG position on subsidies, partnership with the private sector, casts spurious claims on motives and delves into conspiracy theories. The USG supports untargeted subsides when there is no medical downside to overuse and the cost of the treatment is cheap. Deworming kids is the classic example. In our view, a shift towards targeted subsidies approaches make sense given the current malaria epidemiology with decreasing prevalence and concerns of overuse leading to misdiagnosis of other febrile illness and concerns of resistance.

It appears that the concerns were well-founded. In Science, CHAI found that private pharmacies handed out costly malaria drugs indiscriminately to patients with bad fevers without first checking for the parasite. They estimate that more than 400 million doses of malaria drugs went to people without the disease. In some countries, the number of drug doses 'dwarfs the number of actual incident malaria cases that occur.'

Mr. Jack's fails to give voice to USG's commitment to ensuring that interventions targeted for private sector delivery are part of a comprehensive package that includes quality assurance, referrals, supervision, support for supply chain, and other supportive interventions. And he blithely ignores that the U.S. continues to work with partner countries and all parties to apply the lessons learned, support pilot countries, and ensure adherence to WHO guidance on incorporating diagnosis and referral care for patients who may be presenting with other febrile illnesses or severe symptoms.

His citation that “observers suggest US opposition – in turn driving ambivalence towards the AMFm by the World Health Organization, a beneficiary of its support – reflected a reluctance by Washington-based 'Beltway bandits' to lose a share of funding and control' is as reckless and it is baseless. The insinuation is that all global health funders and AMFm working group members are complicit in the ridiculous assertion that AMFM was killed to keep 'Beltway Bandits' flush.

In the article, Mr. Jack denigrates all dedicated public servants and health experts in the U.S. Government and indicts every technical representative in the AMFm working group, for if an anti-private sector case management scheme was at play, all would be party to it -- complicit in silence.

The U.S. is working to ensure key elements of AMFm continue and will allow individual countries to continue to pursue targeted subsidy approaches through the private sector, where there are good reasons to do so, and to design the specifics of how it would work -- these approaches are core to the New Funding Model at the Global Fund and reflect the core principles in the Paris Declaration on Aid Effectiveness.

Chris Thomas
USAID
202 712-1092
chthomas@usaid.gov

On Thu, Apr 25, 2013 at 4:32 AM, SMITALL, Michel wrote:

FT SPECIAL REPORT

Please find attached the Financial Times Special Report on Combating Malaria. This 2013 edition describes progress made to date and expresses fear that an infectious disease claiming 660,000 lives a year is slipping off the agenda. Key issues of the report include the following:


2 attachments
image001.gif 1K
FT_combating_malaria_2013.pdf 5276K
SITE COUNT Amazing and shiny stats
Copyright © 2005-2021 Peter Burgess. All rights reserved. This material may only be used for limited low profit purposes: e.g. socio-enviro-economic performance analysis, education and training.